



Latest oncology clinical development updates

Wednesday, March 26, 2025

[Subscribe here](#)


[Read this newsletter online](#)

OTW News Highlights this week

- [FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient](#)
- [Development of EO-3021 to be Discontinued](#)
- [FDA Orphan Drug Designation for HLX22/AC101 in Gastric Cancer](#)
- [Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933](#)
- [Vobramitamab duocarmazine \(vobra duo\) program to be discontinued](#)
- [RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment](#)
- [Second DSMB Issues Positive Recommendation to Continue Bria-IMT Ph 3 Study in Metastatic Breast Cancer](#)
- [NMPA approves toripalimab combined with bevacizumab for 1L treatment of HCC in China](#)



[Read more Drug Approvals](#)



[Azer-cel granted FDA Fast Track Designation in DLBCL](#)

Leslie Chong, Managing Director and CEO of Imugene, commented: "Receiving FDA Fast Track Designation is a testament to the transformative potential of azer-cel for patients battling relapsed or refractory DLBCL. We are committed to working closely with the FDA to bring this important therapy to patients as efficiently as possible."

[Orphan Drug Designation for HLX22 in the U.S. for Gastric Cancer](#)

"US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the innovative anti-HER2 monoclonal antibody (mAb) for the treatment of gastric cancer."

[Read more Regulatory News](#)



[FRUSICA-2 Ph 2/3 Study of Sintilimab and Fruquintinib Combination Met Primary Endpoint in Advanced RCC in China](#)

Dr Hui Zhou, Senior Vice President of Innovent, stated: “We are encouraged by the positive results in the FRUSICA-2 clinical trial. These outcomes not only underscore the great potential of the combination therapy of sintilimab and fruquintinib but also bring new hope to previously treated patients with advanced renal cell carcinoma. We look forward to working closely with HUTCHMED to ...

[SGO 2025: Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer](#)

“At this year’s SGO, data from the COMPASSION-18 study highlighted the exceptional efficacy seen in patients receiving cadonilimab in combination with CCRT during the safety run-in phase. The results demonstrate the considerable therapeutic potential of cadonilimab combined with CCRT for locally advanced cervical cancer. The study included a more challenging patient cohort, with a notably higher proportion of patients having ...

[Read more Trial Results](#)




[First Participant Dosed in Ph 3 Study of IBI354 for Platinum-resistant Ovarian Cancer](#)

Dr. Zhou Hui, Senior Vice President of Innovent, stated, “I’m pleased that the Phase III clinical study of IBI354 in HER2-expressing PROC has completed the first participant dosing. I look forward to positive results for IBI354 to provide a better treatment option for patients with HER2-expressing PROC. ADC is one of the core technology areas of Innovent's strategic layout. We ...

[Ph 2 FIRCE-1 study of firicabtagene autoleucel \(firi-cel\) to be discontinued](#)

“In connection with the Company’s review of strategic options, the Board has concluded that it is in the best interests of shareholders to cease development operations,” said John Orwin, Chairman of the Board. “We are grateful for the contributions of those who will be leaving CARGO as a result of the decision to discontinue development of our remaining pipeline assets. ...

[Read more Trial Status](#)



[Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Gen Therapeutic Antibodies](#)

Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed, commented: “This strategic collaboration with AstraZeneca marks a significant step in advancing next-generation antibody therapeutics, reinforcing Harbour BioMed’s position as a leader in multi-specific biologics innovation. By leveraging our cutting-edge discovery capabilities and AstraZeneca’s expertise in drug development, we aim to accelerate the creation of transformative therapies for patients ...

[Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer](#)

“We are proud to partner with Roche, a global leader in oncology, to accelerate the application of novel cancer targets identified through our proprietary discovery platform, OGAP-Verify,” said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics. “This collaboration builds on our efforts to enhance, validate and advance the discovery of oncology targets, and we look forward to leveraging ...

[Read more Business News](#)

Editor's Desk

Editor's Desk

Author

- [Richa Tewari, PhD](#)

Managing Editors

- [Shalini Roy Choudhury, PhD](#)
- [Anusha Jayaraman, PhD](#)

Social Media Managers

- [Siftjit Kaur, PhD](#)
- [Himanshi Agarwal, PhD](#)



Disclaimer: The OTW team take care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is a part of RLS Consultants, which is a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.